Overview

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.
Phase:
Phase 3
Details
Lead Sponsor:
Osmotica Pharmaceutical US LLC